A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This study is a Phase II, single center, randomized, double-blind, placebo-controlled study
in male and female subjects, aged ≥ 19 years with mild to moderate seborrheic dermatitis of
the face. All subjects will receive BID topical applications of PAC-14028 cream or vehicle
for up to 4 weeks.